TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17010994
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment (10-20mg/day)
Study: 16234007
Drug: Alvimopan 12
Normalized name: alvimopan 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan 12 mg twice daily with placebo
Study: 16234007
Drug: Alvimopan 12
Normalized name: alvimopan 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan 12 mg twice daily with codeine 30 mg 4 times/day
Study: 16234007
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with codeine 30 mg 4 times/day
Study: 12483729
Drug: IDEC‐131 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDEC‐131 (2.5 mg/kg to 10.0 mg/kg)
Study: 9690596
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (2 mL 0.5% dibucaine)
Study: 9690596
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia (20 mL 2% mepivacaine)
Study: 2686547
Drug: norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin (400 mg three times a day)
Study: 2686547
Drug: pefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: pefloxacin (400 mg three times a day)
Study: 27564925
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (λ of 640 nm and SAEF of 1.06 J/cm2)
Study: 27564925
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy (λ of 660 ± 20 nm and SAEF of 0.24 J/cm2)
Study: 18842959
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group with personally relevant statement
Study: 17257479
Drug: Oral linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral linezolid during hospitalization and after discharge
Study: 17257479
Drug: IV vancomycin/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV vancomycin/oral linezolid switch
Study: 10442373
Drug: Uracil/tegafur (UFT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uracil/tegafur (UFT) 250 mg/m2/day plus oral calcium folinate 45 mg/day
Study: 24698346
Drug: Beta-carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (30 mg/d)
Study: 2213107
Drug: 13-cis retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis retinoic acid (1 mg/kg/d)
Study: 21350025
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IL-6 (rhIL-6) infusion into the peritendinous tissue of the Achilles tendon
Study: 19106357
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (MTX) injected intravascularly at 100 mg/m² plus 200 mg/m² in 500 mL of normal saline solution with folinic acid rescue
Study: 17179377
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (n = 22)
Study: 11230464
Drug: 5 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 cycles of 4'-epidoxorubicin 60 mg/m² days 1 and 2 and ifosfamide 1.8 g/m² days 1 through 5, with hydration, mesna, and granulocyte colony-stimulating factor
Study: 1291521
Drug: 40% citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% citric acid treatment to remove smear layer with Tubliseal
Study: 1291521
Drug: 40% citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% citric acid treatment to remove smear layer with Vitrebond
Study: 1679324
Drug: Rational Emotive
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational Emotive Therapy (RET)
Study: 17429726
Drug: Oral pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pantoprazole (80 mg BID for 3 days)
Study: 17429726
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole (80 mg IV bolus and 8 mg/hr infusion for 3 days)
Study: 14767029
Drug: FTY (0.25-3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY (0.25-3.5 mg)
Study: 14767029
Drug: FTY (0.25-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY (0.25-2 mg)
Study: 14767029
Drug: FTY (0.25-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY (0.25-2 mg) or (3.5 mg)
Study: 14767029
Drug: FTY (high-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY (high-dose)
Study: 11436678
Drug: Isosorbide 5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide 5-mononitrate (Mononit) 10 or 20 mg twice a day
Study: 2575572
Drug: Somatostatin administration
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin administration for two days
Study: 2575572
Drug: No somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No somatostatin administration (Control)
Study: 28591778
Drug: 2D_M0,6 (2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2D_M0,6 (2-dose schedule at months 0 and 6)
Study: 28591778
Drug: 2D_M0,12 (2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2D_M0,12 (2-dose schedule at months 0 and 12)
Study: 28591778
Drug: 3D_M0,1,6 (3-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D_M0,1,6 (3-dose schedule at months 0, 1, and 6)
Study: 26114996
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention with diabetes educators videoconferencing monthly to review glucose and blood pressure readings.
Study: 26114996
Drug: Changing medication
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changing medication dose (as opposed to starting or stopping a medication).
Study: 26114996
Drug: Adjusting glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusting glucose-lowering agents compared with antihypertensive or antilipid medications.
Study: 22890639
Drug: Clazosentan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (5 mg/h)
Study: 16818012
Drug: Cisplatin-based combination
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based combination neoadjuvant chemotherapy
Study: 16818012
Drug: Local therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapy alone
Study: 16818012
Drug: Immediate cystectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate cystectomy with adjuvant chemotherapy
Study: 16818012
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with monitoring of response
Study: 11050519
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.025 mg
Study: 12697594
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.05 mg
Study: 2843255
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin + dihydroergotamine (A)
Study: 2843255
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin + dihydroergotamine (B)
Study: 31420748
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg IR on awakening QD
Study: 31420748
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg DR following breakfast QM
Study: 31420748
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg DR following breakfast QM
Study: 31420748
Drug: DR groups
Normalized name: Dr. Numb
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DR groups (25 mg and 37.5 mg)
Study: 31201692
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine (20 ml of 2.5% bupivacaine hydrochloride)
Study: 31201692
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 ml of bupivacaine)
Study: 19672175
Drug: Ephedrine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (8 mg/ml)
Study: 19672175
Drug: Phenylephrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (100 microg/ml)
Study: 16139450
Drug: Estrogen/hormone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen/hormone therapy (ET/HT) for 3 years
Study: 16139450
Drug: Estrogen/hormone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen/hormone therapy (ET/HT)
Study: 9311511
Drug: Formoterol inhaled
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol inhaled at high flow rate (120 L.min-1)
Study: 9311511
Drug: Formoterol inhaled
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol inhaled at low flow rate (60 L.min-1)
Study: 8318319
Drug: fentanyl 5
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 5 micrograms ml‐1
Study: 8318319
Drug: combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined group (0.125% bupivacaine with fentanyl 5 micrograms ml‐1)
Study: 31693541
Drug: GET Living
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GET Living (graded exposure treatment)
Study: 22573599
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST) for 7 weeks
Study: 21981842
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with rosuvastatin 20 mg and fenofibric acid 135 mg
Study: 21981842
Drug: Rosuvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin monotherapy (10, 20, or 40 mg)
Study: 21981842
Drug: Rosuvastatin 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5, 10, 20, or 40 mg; fenofibric acid 135 mg
Study: 14666012
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg Salvia miltiorrhiza intravenously after anesthesia induction and at the time of rewarming (n=10)
Study: 10705191
Drug: Fiuggi mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiuggi mineral water (oligomineral water with a calcium content of 15 mg/l)
Study: 10705191
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water (calcium content ranging between 55 and 130 mg/l)
Study: 9023787
Drug: Venlafaxine (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (375 mg/day for 10 days, then reduced to 150 mg/day)
Study: 30790557
Drug: HABIT-ILE (hand-arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: HABIT-ILE (hand-arm bimanual intensive therapy) delivered over 2 weeks
Study: 30790557
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (mostly neurodevelopmental) delivered 1-5 times/week
Study: 28379310
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial volume increase (per 5 mL increase)
Study: 23493606
Drug: EE 20
Normalized name: AcidFree 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 20 µg/DRSP 3 mg (flexible extended regimen)
Study: 23493606
Drug: EE 20
Normalized name: AcidFree 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 20 µg/DRSP 3 mg (conventional 28-day cyclic regimen)
Study: 23493606
Drug: EE 20
Normalized name: AcidFree 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 20 µg/DRSP 3 mg (fixed extended regimen)
Study: 17420364
Drug: Topical beta-adrenergic
Normalized name: Beta-HC Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beta-adrenergic antagonists
Study: 12467106
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg glucose
Study: 9117888
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) infusion
Study: 3025246
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HS) infusion
Study: 3025246
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (NS) infusion
Study: 3025246
Drug: CRH administration
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH administration during saline infusions
Study: 28296588
Drug: AppleMetS® (AMS),
Approvals — FDA: no, EMA: no, PMDA: no
Description: AppleMetS® (AMS), 2 capsules a day for one month
Study: 21435021
Drug: 0.06% retinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06% retinyl retinoate cream for 3 months
Study: 20078381
Drug: 0.075% retinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% retinol cream
Study: 18339027
Drug: QFT-G 'In
Approvals — FDA: no, EMA: no, PMDA: no
Description: QFT-G 'In Tube' assay
Study: 18339027
Drug: QFT-G 'In
Approvals — FDA: no, EMA: no, PMDA: no
Description: QFT-G 'In Tube' assay and TST
Study: 16887890
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of disulfiram and naltrexone
Study: 8608540
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HF) at doses of 64.8, 72, 76.8, or 81.6 Gy
Study: 8608540
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated radiation therapy (AHF) at doses of 48 or 54.4 Gy
Study: 8608540
Drug: Carmustine (BCNU)
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine (BCNU) administered with both HF and AHF
Study: 27618639
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (homework‐focused parent training and a daily report card; BPT + DRC)
Study: 23380213
Drug: Chiropractic spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic spinal instrument-based manipulative treatments (9 treatments over 2 weeks)
Study: 29983189
Drug: Standard ointment
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard ointment dressings
Study: 25332325
Drug: Low-genistein (LG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-genistein (LG) supplement (100 mg isoflavones/d)
Study: 25332325
Drug: High-genistein (HG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-genistein (HG) supplement (100 mg isoflavones/d)
Study: 22378566
Drug: Golimumab (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (combined 50 mg and 100 mg)
Study: 10412878
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg daily for 16 weeks)
Study: 10412878
Drug: Fosinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (20 mg daily for 16 weeks)
Study: 7600840
Drug: Corticosteroids (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (low-dose vs. high-dose)
Study: 2393268
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cefpodoxime proxetil (single dose)
Study: 2393268
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cefpodoxime proxetil (steady state, after 5 days)
Study: 2393268
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cefpodoxime proxetil (single dose)
Study: 2393268
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cefpodoxime proxetil (steady state, after 5 days)
Study: 2393268
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing regimens (200 mg and 400 mg)
Study: 7290471
Drug: Silymarin (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (420 mg/die/os)
Study: 25950503
Drug: Topical fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluorouracil cream, 5% (n=468)
Study: 24053647
Drug: HTK with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTK with topical cooling
Study: 24053647
Drug: HTK without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HTK without topical cooling
Study: 21355946
Drug: Iyengar yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iyengar yoga practice (90 min twice weekly for 8 weeks)
Study: 19787222
Drug: Estrogen receptor-beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen receptor-beta (ER-beta) expression
Study: 17096171
Drug: Intraarticular 100
Normalized name: calcium chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular 100 mg of tramadol in 20 ml normal saline and periarticular incisional injection of 10 ml bupivacaine 0.5% (Group TB)
Study: 17096171
Drug: Intraarticular 20
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular 20 ml 0.25% and periarticular incisional 10 ml 0.5% bupivacaine injections (Group BB)
Study: 10726235
Drug: Trazodone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (mean once‐daily dose 111.5 +/- 36.3 mg)
Study: 10726235
Drug: Clorazepate (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate (mean once‐daily dose 17.5 +/- 7.5 mg)
Study: 2029287
Drug: Rectally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectally administered diazepam (R‐DZP)
Study: 6459190
Drug: BCG treatments
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG treatments (all types)
Study: 26262904
Drug: Short-acting oral
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting oral methylphenidate, taken two or three times daily; each dose ranged between 0.3 and 1.0 mg/kg.
Study: 23218404
Drug: Bryophyllum pinnatum
Normalized name: Millettia pinnata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryophyllum pinnatum (BP) 350 mg/day (3×2 capsules)
Study: 12510801
Drug: Teriparatide treatment
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide treatment for a median of 19 months
Study: 11072392
Drug: Coping-skills Relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping-skills Relapse Prevention (RP) treatment
Study: 11072392
Drug: Health Belief
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Belief Model (HBM) treatment
Study: 7576392
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (including fluoride dentifrices)
Study: 6776974
Drug: High-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow oxygen therapy (2 litre min-1 oxygen and 13 litre min-1 air) for 30 min followed by low-flow oxygen therapy (2 litre min-1 dry oxygen) for 30 min
Study: 6776974
Drug: Low-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow oxygen therapy (2 litre min-1 dry oxygen) for 30 min followed by high-flow oxygen therapy (2 litre min-1 oxygen and 13 litre min-1 air) for 30 min
Study: 30905130
Drug: Adjunctive 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive 1,000 mg/day of mangosteen pericarp
Study: 22196196
Drug: Light extrusive
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light extrusive forces (25 g)
Study: 22196196
Drug: Heavy extrusive
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy extrusive forces (225 g)
Study: 21058477
Drug: Ibuprofen capsules
Normalized name: Diphenhydramine Hydrochloride and Ibuprofen Capsules
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen capsules for 30 days
Study: 18186237
Drug: Inhaled bronchodilators
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilators
Study: 15774170
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control of blood glucose by intensive insulin therapy (maintenance of blood glucose at a level between 4.4 and 6.1 mmol/L)
Study: 15774170
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control of blood glucose by intensive insulin therapy
Study: 15774170
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (maintenance of glucose at a level between 10.0 and 11.1 mmol/L)
Study: 11821798
Drug: Hyperthermia combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia combined with chemotherapy and radiotherapy
Study: 11821798
Drug: Intra- or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra- or postoperative hyperthermia treatment
Study: 11821798
Drug: Hyperthermia for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia for unresectable or local recurrent rectal cancer
Study: 7602364
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy for intermediate-grade lymphomas
Study: 7602364
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy or therapy for low-grade lymphoma or Hodgkin's disease
Study: 7602364
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy for intermediate-grade lymphoma
Study: 7602364
Drug: Other therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other therapies (including salvage therapies)